
A meta‐analysis of cardiorenal outcomes of sodium‐glucose co‐transporter‐2 inhibitors (SGLT‐2is) available in Europe or the United States in patients with type 2 diabetes (T2D) is presented. An electronic search up to 6 January 2021 was conducted to determine eligible trials. A total of eight cardiorenal outcomes trials of SGLT‐2is (empagliflozin, canagliflozin, dapagliflozin, ertugliflozin and sotagliflozin) were identified, with 65,587 patients...
Like
Save
Share